An interventional study of Catheter Ablation for Atrial Fibrillation and Rate Control Medications (beta-blockers, calcium channel blockers, digoxin) in Atrial Fibrillation (AF), Heart Failure With Mildly Reduced Ejection Fraction and Heart Failure With Preserved Ejection Fraction (HFPEF), sponsored by Nova Scotia Health Authority. Recruiting at 4 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Nova Scotia Health Authority · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 318 studies in Atrial Fibrillation with a site in Canada — 50 open to participants now, 73 under way, 8 of them phase 3. Atrial Fibrillation · Canada.
Among the 318 studies in Atrial Fibrillation with a site in Canada, this one is the 199th largest by planned enrollment of the 261 interventional ones that give a count, is one of 10 that started in 2026, is one of 135 with no phase, reaches primary completion later than 42 of the 72 other live ones, and was the 312th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →50 of the 318 studies in Atrial Fibrillation with a site in Canada are open now. Recruiting first, the newest first:
Milestone Pharmaceuticals Inc. · Sites in Canada, United States, Netherlands
Ages 18+
Regeneron Pharmaceuticals · Sites in Canada, United States, Japan
Ages 18+
Pavel Antiperovitch · Sites in Canada
Ages 18+
French Cardiology Society · Sites in Canada, France, New Zealand
Ages 18+
Ottawa Hospital Research Institute · Sites in Canada
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
318 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 29 · Phase 3 64 · Phase 4 30
First in 1999; this study’s year is marked. 10 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 84 is below the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 282 across the 261 interventional studies, 297 across the 57 observational. Of the 217 that completed or were terminated, 81 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
128 of 318 have an industry lead sponsor. The 10 most frequent:
Nova Scotia Health Authority is the lead sponsor of 264 studies on the registry; 77 are open to participants now.
Nova Scotia Health Authority has 5 studies filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
24 of the studies in Atrial Fibrillation with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757869Phase 3Janssen Research & Development, LLCA Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | 2026-12-08 |
| NCT02150902Ottawa Heart Institute Research CorporationAugmented Wide Area Circumferential Catheter Ablation for Reduction of Atrial Fibrillation Recurrence | 2026-11-27 |
| NCT07245147Jacqueline JozaREDO-AF: Randomized Evaluation of Dual Options for AF Re-intervention | 2026-12 |
| NCT06249269Ratika ParkashReversal of Atrial Substrate to Prevent Atrial Fibrillation Cohort Study | 2026-12 |
| NCT05600829University of CalgaryA Behavioural Weight Loss Intervention Delivered in Cardiac Rehabilitation for Patients With Atrial Fibrillation and Obesity | 2026-12-30 |
Add all 24 to your calendar (.ics) → With an account.
Among the 318 studies in Atrial Fibrillation with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is testing two different ways of treating atrial fibrillation (AF) in people who also have heart failure with mildly reduced or preserved heart function. Patients will randomly be assigned to either rhythm control using catheter ablation or rate control using medicines. The pilot phase will determine if a larger study can be successfully carried out to see which approach better improves survival, reduces hospitalizations, and enhances quality of life.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this group will undergo catheter ablation procedure, scheduled within 4 weeks of joining the study.
Procedure: Catheter Ablation for Atrial Fibrillation
Participants in this group will take medications, with the dosages adjusted over the first few weeks to find the correct dosage.
Drug: Rate Control Medications (beta-blockers, calcium channel blockers, digoxin)
Participants randomized to this arm will undergo catheter ablation within 4 weeks of randomization. Pulmonary vein isolation is required; additional ablation strategies may be applied at investigator discretion. Guideline-directed medical therapy for atrial fibrillation and heart failure will also be provided.
Participants randomized to this arm will receive pharmacologic therapy to achieve guideline-recommended heart rate control (resting HR \<80 bpm, \<110 bpm with exercise). Therapy may include beta-blockers, non-dihydropyridine calcium channel blockers, or digoxin. If adequate control is not achieved with medication, AV nodal ablation and pacing may be used. Guideline-directed medical therapy for atrial fibrillation and heart failure will also be provided.
Feasibility of Trial Conduct
Recruitment rate (patients recruited per center per month) and crossover rate (percentage of participants switching study arms). Feasibility will be defined as ≥0.7 patients enrolled per center per month and ≤10% crossover.
Time frame: 12 months after randomization
Composite of Cardiovascular Mortality and Heart Failure Hospitalization
Time to first event of cardiovascular death (due to MI, sudden cardiac death, HF, stroke, CV procedures, CV bleeding, or other CV cause) or hospitalization for heart failure (admission \>24h, ED visit, or unscheduled IV diuretic administration).
Time frame: Up to 12 months post-randomization
All-Cause Mortality
Death from any cause
Time frame: Up to 12 months
Cardiovascular Hospitalizations and ED Visits (Non-HF)
Number of hospitalizations or emergency department visits for other cardiovascular causes, including atrial fibrillation.
Time frame: Up to 12 months
Quality of Life: EQ-5D (Euroquol 5D Questionnaire)
EQ5D Will include responses from the Euroquol 5D questionnaire
Time frame: Baseline, 12 months
Quality of Life: AFEQT (Atrial Fibrillation Effect on Quality of Life) Questionnaire
AFEQT- Atrial Fibrillation Effect on Quality of Life Questionnaire (Scored 0-100, 0 is complete disability, 100 is no disability)
Time frame: Baseline, 12 months
Quality of life- KCCQ-12 (Kansas City Cardiomyopathy Questionnaire-12)
KCCQ-12- Kansas City Cardiomyopathy Questionnaire-12 (0-100, 0 is very poor, 100 is excellent)
Time frame: Baseline, 12 months
Atrial Fibrillation Burden
Proportion of time in atrial fibrillation as measured by Holter monitoring and symptom-triggered ECG recordings
Time frame: Baseline, 3, 6, and 12 months
Change in NT-proBNP levels
Change in plasma NT-proBNP levels from baseline to follow-up
Time frame: Baseline, 12 months
Change in Left Ventricular Ejection Fraction (LVEF)
Change in LVEF as measured by echocardiography
Time frame: Baseline, 12 months
Exercise Capacity (6-Minute Walk Distance)
Change in distance walked in 6 minutes from baseline to follow-up
Time frame: Baseline, 12 months
Recruitment Metrics
Recruitment ration of male vs. female participants, refusal rates and reasons.
Time frame: Throughout 12-month recruitment
Procedural Complications
Symptomatic pulmonary vein stenosis, atrio-esophageal fistula, pericardial effusion requiring pericardiocentesis, major bleeding requiring transfusion.
Time frame: Up to 30 days post-ablation procedure
Antiarrhythmic Drug Adverse Events
Incidence of drug-related toxicities (e.g., thyroid, hepatic, pulmonary, proarrhythmia)
Time frame: Up to 12 months
All-Cause Death
Number of deaths from any cause
Time frame: Up to 12 months
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Oct 2027, 21 months after the start.
Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 21 months is below that.
Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nova Scotia Health Authority →